According to a recent article from Morgan Stanley, Johnson & Johnson JNJ has estimated a lead in the pharma industry for total drug sales launched in 2009- 11. JNJ reported these sales have totaled over $1.1 billion.
In the report, Morgan Stanley said, "We expect this momentum to continue as the company works past key 2008-11 patent cliffs and pipeline launches accelerate. In all, we project pharma growth to rebound to a 4.2% CAGR over 2011-14 from a -3.4% CAGR over 2007-10."
Johnson & Johnson closed yesterday at $65.51.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in